12-month outcome with microwave ablation in benign thyroid nodules

Kelly Villa; Maite Rodrigo; Mattia Squarcia; Hanzu Felicia A; Aida Orois; Maria Claro; Castillo Arias Karen Andrea; Mireia Mora

doi:10.1530/endoabs.99.P578

P578

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 P578 | DOI: 10.1530/endoabs.99.P578

ECE2024 Poster Presentations Thyroid (58 abstracts)

12-month outcome with microwave ablation in benign thyroid nodules

Kelly Villa ¹ , Maite Rodrigo ¹ , Mattia Squarcia ¹ , Felicia A Hanzu ¹ , Aida Orois ¹ , Maria Claro ¹ , Karen Andrea Castillo Arias ¹ & Mireia Mora ¹

Err

Author affiliations

¹Hospital Clinic Barcelona, Barcelona, Barcelona, Spain

Most thyroid nodules are benign and majority do not require treatment, except for those large nodules that cause symptoms (compression, hormonal dysfunction and/or esthetic problems). Microwave ablation (MWA) is an attractive therapeutic option because it is minimally invasive, relatively inexpensive, capable of providing coagulative necrosis, and has a short treatment time. In the following, we present the experience of our hospital.

Objective: To evaluate the volumen (V) reduction (VRR: (initial V - final V)/(initial V ×100)) and the evolution of symptoms of thyroid nodules treated with AMO.

Material and methods: Prospective study of 20 patients (17 females, 3 males) with 22 benign, euthyroid thyroid nodules with mild to moderate compressive symptoms, treated with ultrasound-guided AMO, between 2021 and 2023, who were followed for 12 months (evaluated at month 1, 3, 6 and 12 after AMO). Success was defined as VVR greater than 50%.

Results: Twenty patients were evaluated, mean age 64 years, 22 nodules (13 solid and 9 mixed). The VRR during follow-up at 1, 3, 6 and 12 months was 12%, 55%, 56% and 69% respectively. Mean initial volume was 27 mL ± 19, and 10 mL± 11.92 at 12 months. Ablation time was 657 sec ± 369 sec, power 30 W, mean energy used was 1219 ± 1194 (J/mL). Symptomatology remission was present in 18 patients. RRV > 50% was observed at 1, 3, 6 and 12 months in 27%, 56%, 64% and 75% of the nodules, respectively.

Conclusions: Our study suggests that ultrasound-guided AMO is an effective and safe procedure for the treatment of thyroid nodules, with remission of symptoms at 12 months in 90% of patients and showing a successful volume reduction (VRR > 50%) from the first control, reaching 75% at 12 months.